$NVAC
NorthView Acquisition Corp Stock $nvac

$nvac Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023040837 Filed on May 17, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$314.7K	$443.7K	$241.6K
YoY Change	44.67%	83.66%
Operating Profit	-$314.7K	-$443.7K	-$241.6K
YoY Change	44.68%	83.66%
Interest Expense	$122.6K	$1.268M	$3.951M
YoY Change	-91.59%	-67.91%
% of Operating Profit
Other Income/Expense, Net	$1.066M	$100.0K
YoY Change	-26.77%
Pretax Income	$874.3K	$824.0K	$3.709M
YoY Change	-29.43%	-77.78%
Income Tax	$21.91K	$383.1K
% Of Pretax Income	2.51%	46.49%
Net Earnings	$852.4K	$440.9K	$3.709M
YoY Change	-29.69%	-88.11%
Net Earnings / Revenue
Basic Earnings Per Share	$0.14	$0.02	$0.15
Diluted Earnings Per Share	$0.14	$0.02	$153.5K
COMMON SHARES
Basic Shares Outstanding	6.168M shares	24.17M shares	5.194M shares
Diluted Shares Outstanding	5.194M shares	5.194M shares	5.194M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.810K	$55.61K	$510.9K
YoY Change	-98.79%	-89.11%
Cash & Equivalents	$5.811K	$55.61K	$510.9K
Short-Term Investments
Other Short-Term Assets	$229.9K	$292.4K	$378.6K
YoY Change	-34.69%	-22.78%
Inventory
Prepaid Expenses
Receivables			$25.00K
Other Receivables			$0.00
Total Short-Term Assets	$235.7K	$348.0K	$914.5K
YoY Change	-71.69%	-61.95%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.66M	$10.39M	$192.0M
YoY Change	-94.45%	-94.59%
Total Long-Term Assets	$10.66M	$10.39M	$192.0M
YoY Change	-94.45%	-94.59%
TOTAL ASSETS
Total Short-Term Assets	$235.7K	$348.0K	$914.5K
Total Long-Term Assets	$10.66M	$10.39M	$192.0M
Total Assets	$10.90M	$10.74M	$192.9M
YoY Change	-94.35%	-94.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$0.00
YoY Change
Accrued Expenses	$427.0K	$463.0K	$85.59K
YoY Change	231.74%	440.96%
Deferred Revenue
YoY Change
Short-Term Debt	$311.0K	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.967M	$2.654M	$85.59K
YoY Change	1751.82%	3001.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$424.1K	$1.432M	$3.338M
YoY Change	-79.25%	-57.1%
Total Long-Term Liabilities	$424.1K	$1.432M	$3.338M
YoY Change	-79.25%	-57.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.967M	$2.654M	$85.59K
Total Long-Term Liabilities	$424.1K	$1.432M	$3.338M
Total Liabilities	$3.391M	$4.087M	$3.424M
YoY Change	53.9%	19.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.874M	-$3.307M
YoY Change	156.45%
Common Stock	$519.00	$519.00
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.874M	-$3.307M	-$2.200M
YoY Change
Total Liabilities & Shareholders Equity	$10.90M	$10.74M	$192.9M
YoY Change	-94.35%	-94.43%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$852.4K	$440.9K	$3.709M
YoY Change	-29.69%	-88.11%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$273.3K	-$966.6K	-$230.4K
YoY Change	329.4%	319.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$146.1K	$185.7M
YoY Change	-536.44%
Cash From Investing Activities	-$146.1K	$185.7M
YoY Change	-536.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	369.6K	-$184.8M
YoY Change
NET CHANGE
Cash From Operating Activities	-273.3K	-$966.6K	-230.4K
Cash From Investing Activities	-146.1K	$185.7M
Cash From Financing Activities	369.6K	-$184.8M
Net Change In Cash	-49.80K	-$137.9K	-230.4K
YoY Change	65.12%	-40.14%
FREE CASH FLOW
Cash From Operating Activities	-$273.3K	-$966.6K	-$230.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41177
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3437271
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	207 West 25th St
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	9th Floor
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10001
CY2023Q1	dei	City Area Code CityAreaCode	(212)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	494-9022
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6167882	shares
CY2023Q1	us-gaap	Cash Cash	55610	usd
CY2022Q4	us-gaap	Cash Cash	193486	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	292358	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	318218	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	347968	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	194736486	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	511704	usd
CY2023Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	10392055	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	194224782	usd
CY2023Q1	us-gaap	Assets Assets	10740023	usd
CY2022Q4	us-gaap	Assets Assets	194736486	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	463009	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	448480	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1848455	usd
CY2023Q1	nvac	Income Tax Payable IncomeTaxPayable	302680	usd
CY2022Q4	nvac	Income Tax Payable IncomeTaxPayable	462271	usd
CY2023Q1	nvac	Due To Related Party DueToRelatedParty	40000	usd
CY2022Q4	nvac	Due To Related Party DueToRelatedParty	25000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2654144	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	935751	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1343	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	36940	usd
CY2023Q1	us-gaap	Other Liabilities OtherLiabilities	1431924	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	857787	usd
CY2023Q1	us-gaap	Liabilities Liabilities	4087411	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1830478	usd
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	974132	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	18975000	shares
CY2023Q1	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.22
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.2
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	9959265	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	193525484	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5193750	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5193750	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5193750	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5193750	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	519	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	519	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3307172	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-619995	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3306653	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-619476	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10740023	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	443717	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	241596	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-443717	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-241596	usd
CY2023Q1	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	1845005	usd
CY2022Q1	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	72684	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3165	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	574137	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3877929	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	1267703	usd
CY2022Q1	us-gaap	Interest Income Operating InterestIncomeOperating	3950613	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	823986	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3709017	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	383091	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	440895	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3709017	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5193750	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5193750	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-619476	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1279617	usd
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-1848455	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	440895	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3306653	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-5909230	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3709017	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2200213	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	440895	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3709017	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1845005	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	72684	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3165	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	574137	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3877929	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-35597	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-25860	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-32167	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	14529	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-19310	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-159591	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	15000	usd
CY2022Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-1613	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-966607	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-230352	usd
CY2023Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	48707	usd
CY2023Q1	us-gaap	Proceeds From Decommissioning Fund ProceedsFromDecommissioningFund	184845836	usd
CY2023Q1	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	877438	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	185674567	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-184845836	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-184845836	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-137876	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-230352	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193486	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	741228	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55610	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	510876	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	597437	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	1848455	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	1279617	usd
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2021Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	189750000	usd
CY2023Q1	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1
CY2023Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	7959726	usd
CY2023Q1	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	3450000	usd
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	3570576	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	259527	usd
CY2023Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	679623	usd
CY2023Q1	us-gaap	Fair Value Investments Entities That Calculate Net Asset Value Per Share Percent Arbitrage Investments FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentArbitrageInvestments	0.80	pure
CY2021Q4	nvac	Maturity Days MaturityDays	P185D
CY2021Q4	us-gaap	Shares Acquired Weighted Average Discount To Net Assets Percentage SharesAcquiredWeightedAverageDiscountToNetAssetsPercentage	1	pure
CY2023Q1	us-gaap	Other Expenses OtherExpenses	100000	usd
CY2023Q1	nvac	Net Tangible Assets NetTangibleAssets	5000001	usd
CY2023Q1	us-gaap	Cash Cash	55610	usd
CY2023Q1	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	1947395	usd
CY2023Q1	us-gaap	Partners Capital Account Contributions PartnersCapitalAccountContributions	25000	usd
CY2023Q1	nvac	Unsecured Promissory Note UnsecuredPromissoryNote	204841	usd
CY2023Q1	nvac	Repurchase Percentage RepurchasePercentage	1	pure
CY2023Q1	nvac	Extension Fee ExtensionFee	48707	usd
CY2023Q1	us-gaap	Preferred Stock Redemption Amount PreferredStockRedemptionAmount	184845836	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.01	pure
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	18000868	shares
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	184845836	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1848455	usd
CY2023Q1	nvac	Shares Redeemed Percentage SharesRedeemedPercentage	0.01	pure
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Concentration of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022	us-gaap	Debt Instrument Term DebtInstrumentTerm	P185D
CY2023Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P185D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	862500	shares
CY2022Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable		usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	194224782	usd
CY2022	us-gaap	Closed Block Dividend Obligation Change In Unrealized Investment Gains Losses ClosedBlockDividendObligationChangeInUnrealizedInvestmentGainsLosses	43626	usd
CY2022	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	194268408	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.4649	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2023Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	21	usd
CY2022Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	21	usd
CY2022Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments		usd
CY2022Q1	us-gaap	Proceeds From Decommissioning Fund ProceedsFromDecommissioningFund		usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	17404250	shares
CY2023Q1	us-gaap	Limited Partners Offering Costs LimitedPartnersOfferingCosts	7959726	usd
CY2023Q1	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	3450000	usd
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	3570576	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	259527	usd
CY2023Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	679623	usd
CY2023Q1	nvac	Payment Of Stock Issuance Costs PaymentOfStockIssuanceCosts	7701178	usd
CY2023Q1	nvac	Shares Of Common Stock SharesOfCommonStock	17404250	shares
CY2021Q2	us-gaap	Sponsor Fees SponsorFees	25000	usd
CY2021Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.005
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022	nvac	Gross Proceeds GrossProceeds	189750000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4204248	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Limited Partners Units ProceedsFromIssuanceOfCommonLimitedPartnersUnits	7701178	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	15680910	usd
CY2022	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	193525484	usd
CY2023Q1	nvac	Partial Redemption PartialRedemption	-184845836	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1279617	usd
CY2023Q1	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	9959265	usd
CY2023Q1	us-gaap	Net Asset Value Per Share NetAssetValuePerShare	9.2
CY2023Q1	nvac	Equity Proceed Ownership Percentage EquityProceedOwnershipPercentage	0.60	pure
CY2023Q1	us-gaap	Share Price SharePrice	18
CY2023Q1	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	●in whole and not in part; ● at a price of $0.01 per warrant; ● upon a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”); ● if, and only if, the last sale price of the common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.
CY2022Q1	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On December 20, 2021, the Company effected a 1.1- for-1 stock dividend of its common stock, resulting in the Sponsor holding an aggregate of 4,743,750 shares of common stock. The Founder Shares include an aggregate of up to 618,750 shares subject to forfeiture if the over-allotment option is not exercised by the underwriters in full.
CY2023Q1	nvac	Common Stock Exceeds Per Share CommonStockExceedsPerShare	12
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	200000	usd
CY2023Q1	us-gaap	Other Borrowings OtherBorrowings	200000	usd
CY2023Q1	nvac	Additional Advanced From Sponsor AdditionalAdvancedFromSponsor	4841	usd
CY2022Q2	nvac	Promissory Note PromissoryNote	25000	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1500000	usd
CY2023Q1	nvac	Warrants Price Per Share WarrantsPricePerShare	1
CY2023Q1	nvac	Rental Expenses RentalExpenses	5000	usd
CY2023Q1	us-gaap	Payment For Administrative Fees PaymentForAdministrativeFees	15000	usd
CY2022Q1	us-gaap	Payment For Administrative Fees PaymentForAdministrativeFees	15000	usd
CY2023Q1	nvac	Business Combination Percentage BusinessCombinationPercentage	0.0368	pure
CY2023Q1	nvac	Gross Proceeds Amount GrossProceedsAmount	6986250	usd
CY2023Q1	nvac	Business Combination Percentage Rate BusinessCombinationPercentageRate	0.0368	pure
CY2023Q1	nvac	Cash Percentage CashPercentage	0.275	pure
CY2023Q1	nvac	Equity Percentage EquityPercentage	0.725	pure
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	3570576	usd
CY2023Q1	nvac	Exercisable Per Share ExercisablePerShare	11.5
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q1	us-gaap	Equity Fair Value Disclosure EquityFairValueDisclosure	155000000	usd
CY2023Q1	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	155000000	pure
CY2023Q1	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	3875000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021Q2	us-gaap	Sponsor Fees SponsorFees	25000	usd
CY2021Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.005
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	862500	shares
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022	nvac	Gross Unrealized Losses GrossUnrealizedLosses		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5193750	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5193750	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2021Q4	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	the Company effected a 1.1- for-1 stock dividend of its common stock, resulting in an aggregate of 4,743,750 Founder Shares issued and outstanding. On December 22, 2021, the Company has also issued 450,000 shares (Representative’s Shares) of common stock (which included 37,500 Representative Shares issued pursuant to the full exercise of the over-allotment option) at the consummation of the IPO to I-Bankers and Dawson James (and/or their designees).
CY2023Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	5193750	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	5193750	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5193750	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5193750	shares
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	974132	shares
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	18975000	shares
CY2023Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	1431924	usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	857787	usd
CY2023Q1	nvac	Aggregate Value Of Public Warrants AggregateValueOfPublicWarrants	759000	usd
CY2022	nvac	Aggregate Value Of Public Warrants AggregateValueOfPublicWarrants	450656	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0476	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0474	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P80Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P90Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.084	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.077	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	10.34	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	10.13	usd
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	NorthView Acquisition Corp
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001859807

Files In Submission

Name	View Source	Status
0001213900-23-040837-index-headers.html	Edgar Link	pending
0001213900-23-040837-index.html	Edgar Link	pending
0001213900-23-040837.txt	Edgar Link	pending
0001213900-23-040837-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_northviewacq.htm	Edgar Link	pending
f10q0323ex31-2_northviewacq.htm	Edgar Link	pending
f10q0323ex32-1_northviewacq.htm	Edgar Link	pending
f10q0323ex32-2_northviewacq.htm	Edgar Link	pending
f10q0323_northviewacq.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvac-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nvac-20230331_def.xml	Edgar Link	unprocessable
nvac-20230331_cal.xml	Edgar Link	unprocessable
nvac-20230331_pre.xml	Edgar Link	unprocessable
f10q0323_northviewacq_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nvac-20230331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAC
NorthView Acquisition Corp Stock $nvac

2023 Q2 Form 10-Q Financial Statement

#000121390023040837 Filed on May 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAC NorthView Acquisition Corp Stock $nvac

2023 Q2 Form 10-Q Financial Statement

#000121390023040837 Filed on May 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAC
NorthView Acquisition Corp Stock $nvac